In NSCLC, head and neck cancer, and melanoma, the total baseline tumor size (total BTS), which is the sum of the diameters of measurable lesions before treatment begins, is reportedly a significant prognostic factor in patients receiving therapy, including PD-1/PD-L1 inhibitors (23–26). This evidence concerns the gene CD274 and non-small cell lung carcinoma.